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Abstract
Nut consumption is associated with a reduced risk of type 2 diabetes mellitus (T2DM). The aim of the present study was to assess the
effects of adding peanuts (whole or peanut butter) on first (0–240 min)- and second (240–490 min)-meal glucose metabolism and selected
gut satiety hormone responses, appetite ratings and food intake in obese women with high T2DM risk. A group of fifteen women partici-
pated in a randomised cross-over clinical trial in which 42·5 g of whole peanuts without skins (WP), peanut butter (PB) or no peanuts
(control) were added to a 75 g available carbohydrate-matched breakfast meal. Postprandial concentrations (0–490 min) of glucose, insu-
lin, NEFA, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), cholecystokinin (CCK), appetitive sensations and food intake were assessed
after breakfast treatments and a standard lunch. Postprandial NEFA incremental AUC (IAUC) (0–240 min) and glucose IAUC (240–490 min)
responses were lower for the PB breakfast compared with the control breakfast. Insulin concentrations were higher at 120 and 370 min
after the PB consumption than after the control consumption. Desire-to-eat ratings were lower, while PYY, GLP-1 and CCK concentrations
were higher after the PB intake compared with the control intake. WP led to similar but non-significant effects. The addition of PB to break-
fast moderated postprandial glucose and NEFA concentrations, enhanced gut satiety hormone secretion and reduced the desire to eat. The
greater bioaccessibility of the lipid component in PB is probably responsible for the observed incremental post-ingestive responses
between the nut forms. Inclusion of PB, and probably WP, to breakfast may help to moderate glucose concentrations and appetite in
obese women.
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The incidence and prevalence of type 2 diabetes mellitus
(T2DM) have increased markedly worldwide, and its compli-
cations are the leading causes of morbidity and premature
mortality(1). The importance of diet in the prevention,
treatment and control of T2DM has been recommended(2).
It has been reported that nut consumption may improve
glycaemic control(3).
Peanut consumption may moderate appetite, food intake
and glycaemic control, and has been negatively associated
with type 2 diabetes risk(4). These beneficial effects may be
due to their nutritional components. Besides being a
low-glycaemic-index food, peanuts are energy dense, and a
good source of fibre, protein, niacin, folate, Mg, Se and Mn.
They also contain bioactive compounds that exert
antioxidant and anti-inflammatory effects(5). However, the
mechanisms responsible for their health benefits have not
been completely elucidated(6).
Processing whole nuts to butter form results in cell-wall rup-
ture and greater fat and fat-soluble nutrient bioaccessibility(7).
The higher availability of fat in the intestinal lumen may
decrease the rate of carbohydrate absorption (by delaying gas-
tric emptying), favouring a reduced glycaemic response, and
stimulate the secretion of intestinal hormones that may curb
appetite and food intake as well as stimulate insulin release(8).
Therefore, the form in which peanuts are consumed (whole or
butter) may lead to different metabolic responses(9).
*Corresponding author: Caio E. G. Reis, fax þ55 31 38992541, email caioedureis@gmail.com
Abbreviations: CCK, cholecystokinin; GLP-1, glucagon-like peptide-1; IAAC, incremental area above the curve; IAUC, incremental AUC; PB, peanut butter;
PYY, peptide YY; T2DM, type 2 diabetes mellitus; WP, whole peanuts without skins.
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The aim of the present study was to assess the effects of
peanut consumption (whole peanuts or peanut butter) on
first- and second-meal glucose metabolism (blood glucose,
insulin and NEFA) and selected gut satiety hormone responses
(glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) and
peptide YY (PYY)), subjective appetite ratings (visual ana-




Study participants were recruited through public advertise-
ments. Eligibility criteria included the following: age 18–50
years; BMI 30–35 kg/m2; not taking medications known to
affect glycaemia, fat metabolism or appetite; regular breakfast
consumer ($420 kJ ingested within 2 h of waking on $4 d/
week); limited body weight fluctuation (,5 kg in the past
3 months); willingness to eat all test foods; no self-reported
allergy to the foods provided in the study; no self-reported
sleep disorders. In addition to the aforementioned criteria,
participants had to meet one of the following conditions:
waist circumference $88 cm; reported family history of
T2DM in first-degree relatives; fasting capillary blood glucose
5·5–7·0 mmol/l; and/or 2 h blood glucose 7·8–11·1 mmol/l
(impaired glucose tolerance). Participants presenting with
T2DM, dyslipidaemia or high blood pressure were excluded.
A total of 141 individuals completed the first screening visit,
of which sixty-eight were eligible for and completed the
second screening visit. Finally, fifteen participants met all
screening criteria and completed the full study protocol.
The protocol was approved by the Human Research Ethics
Committee of the Federal University of Viçosa, Brazil (no. 004/
2009). The present trial was registered at ClinicalTrials.gov
(registration no. NCT01413126). All volunteers were informed
about the objectives of the study and provided written
informed consent. Power calculations indicated that thirteen
individuals were necessary to detect a change in blood
glucose of 0·35 mmol/l (a ¼ 0·05; power ¼ 0·80, SD 0·3)(10).
Study design
The present randomised cross-over clinical trial required
participants to complete three experimental sessions where
whole peanuts without skins (WP), peanut butter (PB) or no
peanuts (control) were consumed with a breakfast meal
separated by a washout period of at least 8 d. Participants
were instructed not to consume alcohol or conduct any
non-habitual physical activity 24 h before the sessions, and
to consume a low-carbohydrate meal the night before the
test sessions. Postprandial concentrations of blood glucose,
insulin, NEFA, GLP-1, CCK, PYY, appetite sensations and
food intake were assessed before and after breakfast treat-
ments and a standard lunch (Fig. 1).
For screening, participants arrived in the laboratory
between 07.30 and 08.00 hours after a 12 h overnight fluid
and feed deprivation for the 2 h oral glucose tolerance test,
and for measurement of height, waist circumference, body
weight, body composition, resting energy expenditure and
blood pressure. Participants were also asked to answer ques-
tionnaires regarding stress, physical activity and eating and
sleeping habits.
At each experimental session, body weight, capillary
glucose level, the number of hours of sleep the night
before and the time and composition of the last meal were
assessed. Finger stick blood glucose was measured using a
glucometer One Touch Ultra 2 (Johnson & Johnson Company)
to ensure that the participants were feed-deprived (glucose
,5·5 mmol/l).
An indwelling catheter was placed in the participant’s fore-
arm and blood samples were drawn and appetite was rated at
baseline (210) and at 15, 45, 60, 90, 120, 180 and 240 min
after test breakfast completion (first-meal responses). At
240 min, participants consumed a standard lunch. Afternoon
blood sampling and appetite scoring occurred at 265, 295,
310, 340, 370, 430 and 490 min after consumption of the test
breakfast (second-meal responses), resulting in a total of 8 h
of biochemical assessment. After leaving the laboratory,
participants recorded all food consumed and filled out the
appetite ratings(11) at 550, 610, 670 and 730 min.
Participants were not allowed to eat or drink anything
(except water) besides the foods that were provided during
the study sessions. They were also not allowed to watch
any television show or talk about anything related to food,
or anything that could affect the assessed parameters. They
were allowed to read, listen to music, watch TV, use the
computer and walk inside the laboratory.
Anthropometric and body composition measurements
Body weight was assessed using an electronic platform scale
(Model 2096 PP, Toledo Brazil), with a capacity for 150 kg
and precision of 50 g. Height was measured using a stadi-
ometer (SECA model 206; Seca) fixed to the wall. BMI was
computed based on weight (kg) and height (m2) (kg/m2),
B
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Fig. 1. Experimental study protocol. B, breakfast; L, lunch; LL, leave the laboratory; A, appetite; P, palatability; , glucose, insulin, NEFA, glucagon-like peptide-1
(GLP-1), cholecystokinin and peptide YY analyses; , glucose, insulin, NEFA and GLP-1 analyses.

















and classified according to the parameters of the WHO(12).
Waist circumference was measured midway between the
lowest rib and the iliac crest with a precision of 0·1 cm(13),
and classified according to the parameters of the Third
Report of the National Cholesterol Education Program Expert
Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults(14). Body fat percentage was
measured by tetrapolar electrical bioimpedance (Biodynamics,
Model 310, TBW) according to the protocol of Lukaski
et al.(15). Participants were instructed not to use diuretics 7 d
before the assessment, not to exercise during the preceding
12 h, not to drink alcohol for the preceding 48 h and to
avoid drinking any beverage 12 h before the test.
Clinical assessments
Blood pressure was assessed by auscultation with a recently
calibrated aneroid sphygmomanometer. The measurement
was performed during the initial evaluation by a trained
professional, and classification of the values obtained was
done according to the recommendations by Pickering et al.(16).
The level of physical activity was estimated using the
Johansson & Westerterp(17) questionnaire. Energy expenditure
was estimated by multiplying the physical activity level
obtained by the BMR calculated using the Mifflin et al.
equation(18).
Participants were instructed to eat a hypoglycaemic meal
for dinner on the night before. This meal was intended to
contain only meat and vegetables. High-carbohydrate foods
(i.e. breads, rice, pasta, potatoes, cassava, etc.) were not
allowed. Once the participants arrived at the laboratory, their
feed-deprived state was verified (One Touch Ultra 2, Johnson
& Johnson Company). An oral glucose tolerance test was
performed on screening day and the participants were
classified according to the American Diabetes Association(19).
Homeostasis model assessment insulin resistance index was
used to evaluate insulin resistance level. Pancreatic b-cell
function was assessed by homeostasis model assessment
pancreatic b-cell function according to the Matthews et al.
equation(20). According to Geloneze et al.(21), the cut-off
point for insulin resistance diagnosis in Brazilian obese
women aged approximately 40 years is 2·71.
Test meal
In accordance with the Food and Drug Administration(22)
-qualified health claim regarding daily nut intake, 42·5 g of
WP or PB were added to a breakfast meal in each test session.
On each testing occasion, each participant consumed a test
breakfast within 10 min that consisted of orange juice
(250 ml) (Tropical Indústria de Alimentos S/A.) and cereal-
containing treatment WP, PB or control (no peanuts) in
randomised order. The cream of wheat was prepared by
adding 56 g of instant cream of wheat (Original Instant
Cream of Wheat, B&G Foods, Inc.) to brown sugar
(P¼8·7 g; PB ¼ 9·6 g; control ¼ 9·9 g) (Lowçucar, LightSweet,
Inc.), 1 g of aspartame sweetener (NutraSweet Company)
and 300 ml of water, which was then heated for 1·5 min in
the microwave. For the peanut treatments, 42·5 g of whole
peanuts without skins (Nuts Online Company) (WP treatment)
or creamy peanut butter (Arrowhead Mills, The Hain Celestial
Group, Inc.) (PB treatment) were added. At minute 240,
participants consumed a standard lunch within 10 min that
consisted of white bread (50 g) (Seven Boys LTDA), straw-
berry jam (89·3 g) (Fugini Alimentos LTDA) and water
(250 ml) containing 75 g of available carbohydrate (Table 1).
Test breakfasts and lunch meals were matched on palatability,
evaluated by appearance, smell, texture and intensity of taste
(sweet, salty, bitter and sour)(11).
The breakfast meal’s glycaemic index was estimated using
the International Glycemic Index Table(23), according to the
Wolever & Jenkins(24) equation (see Supplementary infor-
mation, available online).
Biochemical measurements
A measure of 3 ml of blood was collected in a red top vacutai-
ner at each draw. After clotting and centrifugation, insulin,
glucose and NEFA concentrations were measured. A measure
of 4 ml of blood was collected in an ice-cooled EDTA-plasma
vacutainer, and 40ml of dipeptidyl peptidase-4 inhibiter
(Millipore) was added for analysis of GLP-1, and 325ml
aprotinin (500 KIU/ml) (Sigma-Aldrich) was added for PYY
and CCK analyses; all samples were handled according to
the manufacturer’s directions. Insulin and glucose were
measured by electrochemiluminescence and the glucose
Table 1. Test breakfast and lunch nutritional composition*
Breakfast
Control Peanuts PB Lunch
Energy (kJ) 1408 2514 2561 1442
Fat (g) 0·1 21·2 22·6 1·5
Total carbohydrate (g) 77·9 85·2 85·6 77·6
Available carbohydrate (g) 75·9 81·8 80·9 75·0
Protein (g) 6·0 17·3 16·6 5·2
Fibre (g) 2·0 3·4 4·7 2·6
Glycaemic index 60·8 56·2 58·4 88·5
Example of foods provided Cream of
wheat þ OJ
Cream of
wheat þ OJ þ 42·5 g WP
Cream of wheat þ
OJ þ 42·5 g PB
White bread þ
strawberry jam
OJ, orange juice; WP, whole peanuts without skins; PB, peanut butter.
* Based on nutrition label information.

















oxidase method, respectively. Sensitivity of the insulin
immunoassay was 1·39 pmol/l (within-run CV of 1·9 %). The
glucose oxidase sensitivity was 0·12 mmol/l (within-run CV
of 0·41 %). NEFA were analysed by an enzymatic colorimetric
method on an automated analyser with a sensitivity of
0·14mmol/l (within-run CV of 0·75 %). GLP-1, PYY and CCK
were assessed by ELISA. Sensitivity of the GLP-1 assay
was 2 pmol/L (within-run CV of 7·4 %) (Linco Research),
PYY sensitivity was 1·4 pg/ml (within-run CV of 0·86 %)
(Millipore) and CCK sensitivity was 3·86 ng/ml (within-run
CV ,10 %) (Ray Biotech, Inc.).
Appetite profile
Appetite ratings – hunger, satiety, desire to eat and desire to
consume specific food types (salty, sweet or greasy) – were
scored at baseline and immediately after blood sample collec-
tion on a 100 mm visual analogue scale anchored with descrip-
tors of ‘not at all’ and ‘extremely’(11). The visual analogue scales
were completed eight times throughout the test day at 210, 15,
45, 60, 90, 120, 180 and 240 min after consumption of the test
breakfast (first-meal responses) and seven times at 265, 295,
310, 340, 370, 430 and 490 min (second-meal responses). After
leaving the laboratory, participants recorded all food consumed
and filled out the appetite ratings at 550, 610, 670 and 730 min.
Therefore, appetite ratings were assessed for a total of 12 h.
Food intake assessment
Before the beginning of the study, all participants were
instructed to register their food intake on three non-consecutive
days (two week days and one weekend day)(25) to describe their
eating habits at baseline. In addition, after leaving the laboratory
(490 min), participants were asked to keep a food record for the
rest of the day. To ensure accuracy, participants received written
guidelines and were trained to estimate the consumed food por-
tions using household items. Participants received a standar-
dised record form to register the type and amount of foods
and beverages consumed before the beginning of the study
(baseline) and after they left the laboratory on each test meal
day. Each dietary record was reviewed in the presence of the
volunteer in order to ensure its accuracy and completeness.
Food portions were converted into grams and the subsequent
meal energy intake, 24 h total post-meal energy intake, macro-
nutrients and fibre consumption were analysed using the soft-
ware DietPro 5.0i (A.S. System).
Statistical analyses and calculations
While the incremental AUC (IAUC) (glucose, insulin, GLP-1,
PYY, CCK and appetite sensations) was calculated excluding
the values below the baseline values, the incremental area
above the curve (IAAC; NEFA) was obtained excluding any
value above (IAAC) the baseline values(26). IAUC and IAAC
were computed using the trapezoidal method, using Slide
Write software, version 7.0 (Advanced Graphics Software,
Inc.). Data analyses were conducted considering the following
periods of time: 0–490 min (defined as the whole study
response), 0–240 min (defined as the first-meal response),
240–490 min (defined as the second-meal response) and
490–730 min (defined as the post-laboratory period).
Residual plots of data were examined to consider homogen-
eity of variance and the Shapiro–Wilk test was performed to
determine data distribution normality, and a logarithmic trans-
formation was used when required. Repeated-measures
ANOVA was used to examine the effects of meal and time on
the postprandial responses and appetite sensations. This was
performed using PROC MIXED (SAS, version 9.1). Post hoc com-
parisons were made using Bonferroni adjustments for meal and
for meal £ time interactions when significant. ANOVA was used
to examine the effect of meal on IAUC, IAAC and food intake,
and, when appropriate, post hoc comparisons were made
using the Tukey’s test. PROC TTEST (SAS, version 9.1) was
applied to compare morning v. afternoon IAUC/IAAC and
peak values of each treatment on each variable. All statistical
analyses were performed using the Statistical Analysis System
software package, version 9.1 (SAS Institute, Inc.). The criterion
for statistical significance was P,0·05 (two-tailed). The results
related to the characterisation of the sample and dietary intake
are presented as mean values and standard deviations, and bio-
chemistry and appetite responses are presented as mean values
with their standard errors.
Results
Participant characteristics
Two participants did not return their visual analogue scale
and diet records and data analyses were conducted on
thirteen participants. Their baseline characteristics are shown
in Table 2. There were no differences in body weight
(P¼0·95), capillary glucose (P¼0·93) and number of hours
of sleep (P¼0·39) before the beginning of each experimental
session. None of the feed-deprived variables assessed in the
study differed (P.0·78).
Blood glucose
Although the first-meal glycaemic response IAUC did not
differ between the breakfast treatments (P¼0·48), the
Table 2. Baseline characteristics of the participants
(Mean values and standard deviations)
Variables Mean SD
Age (years) 8·61 35·33
Waist circumference (cm) 100·77 6·34
BMI (kg/m2) 32·36 1·25
Body fat (%) 36·74 3·56
Systolic blood pressure (mmHg) 118·00 7·75
Diastolic blood pressure (mmHg) 76·00 7·37
Feed-deprived blood glucose (mmol/l) 4·99 0·49
Blood glucose OGTT (mmol/l) 6·06 1·39
HOMA-IR* 2·79 1·43
HOMA1-b%† 50·22 22·56
OGTT, oral glucose tolerance test; HOMA-IR, homeostasis model assess-
ment insulin resistance index; HOMA1-b, homeostasis model assessment
pancreatic b-cell function
* HOMA-IR ¼ (fasting insulin (mU/ml) £ fasting glucose (mmol/l))/22·5.
(Insulin: 1 mU/ml ¼ 6·945 pmol/l.)
† HOMA1-b ¼ (20 £ fasting insulin (mU/ml))/(fasting glucose (mmol/l)–3·5).
(Insulin: 1 mU/ml ¼ 6·945 pmol/l.)

















ingestion of the PB meal resulted in significantly lower
second-meal glycaemic response IAUC (P¼0·03), as
compared with the control breakfast. The PB and the WP
meals’ glucose IAUC responses (0–490 min) were 18·7 and
14·4 % lower than the control meal (P¼0·48), respectively
(Table 3). The inclusion of peanuts reduced the glycaemic
index of the breakfast meals from 60·8 (control) to 56·2 (PB)
and 58·4 units (WP) (Table 1).
There was a time £ meal interaction on the first-meal post-
prandial glycaemic response (P¼0·03). Post hoc comparisons
indicated a lower glucose concentration at 15 and 310 min
(both P¼0·04), and a tendency for lower glucose concen-
tration at 45 min (P¼0·05) after the PB compared with the
control breakfast (Fig. 2(a)). Mean first- (15 min) and
second-(295 min) meal glucose peaks did not differ
(P.0·26) according to the study treatment. The first-meal gly-
caemic IAUC responses for all treatments were significantly
lower (P,0·03) than the second-meal responses.
Serum insulin
The WP and the PB meals’ insulin IAUC responses (0–490 min)
were 50·2 and 23·1 % higher than the response to the control
meal (P¼0·53), respectively (Table 3). Post hoc comparisons
indicated a higher insulin concentration for the WP meal at
45 min (P¼0·03) and for the PB meal at 120 (P¼0·04) and
370 min (P¼0·02) compared with the control breakfast
(Fig. 2(b)). The first-meal insulinaemic response peaks (WP:
45 min; PB: 15 min; and control: 15 min) were higher
(P,0·04) compared with the second meal (WP: 310 min; PB:
370 min; and control: 295 min) for all the treatments. The WP
and the PB first-meal insulinaemic responses (P,0·002) were
higher compared with the second-meal responses.
NEFA
The PB first-meal (0–240 min) NEFA IAUC was lower
(P¼0·02) compared with the control breakfast. The WP and
the PB NEFA IAUC responses (0–490 min) were 44·0 and
21·4 % lower than that obtained for the control meal
(P¼0·06), respectively (Table 3). There was a time £ meal
interaction on the first-meal postprandial NEFA response
(P¼0·002). Post hoc comparisons indicated a lower NEFA con-
centration at 90 (P¼0·02) and 120 min (P¼0·02), and a ten-
dency for lower NEFA concentration at 180 min (P¼0·06)
after the PB compared with the control breakfast (Fig. 2(c)).
Peak NEFA did not differ between the first and the second
meals according to the study treatment (P.0·44). There was
no difference between the meal time period for NEFA IAUC
responses among the study treatments.
Glucagon-like peptide-1
The WP and the PB GLP-1 IAUC responses (0–490 min)
were markedly but not significantly higher (116·5 and
131·0 %, respectively) than the observed rise for the control
meal (P¼0·46) (Table 3). GLP-1 concentrations did not vary
































































































































































































































































































































































































































































































































































































































































































































































































































































































meal GLP-1 response (P¼0·008) was higher compared with
the second-meal response. Peak GLP-1 did not differ
between the first and the second meals according to study
treatment (P.0·32).
Peptide YY
The PB and the WP first-meal (0–240 min) PYY IAUC were
higher (P¼0·006) compared with the control breakfast
(Table 3). There was also a time £ meal interaction on the
first-meal postprandial PYY response (P¼0·004). Post hoc
comparisons indicated a higher PYY concentration at 120
(P¼0·04), 180 (P¼0·01) and 240 min (P¼0·01) after the WP
compared with the control breakfast (Fig. 3(b)).
Cholecystokinin
The WP first-meal CCK IAUC responses (0–240 min) were
three-fold higher, albeit not significantly, than the control
meal (P¼0·65) (Table 3). CCK concentrations did not vary sig-
nificantly between the treatments (Fig. 3(c)).
Appetite sensations
During the post-laboratory period (490–730 min), the WP and
the PB IAUC desire to eat were lower (P¼0·04) compared
with the control breakfast. However, self-reported fullness
was significantly higher at 610 min after the control compared
with the WP (P¼0·001) and the PB (P¼0·01) breakfast con-
sumption. There was a lower desire to eat something fatty at
610 and 670 min after the control compared with the WP
(P¼0·02) and the PB (P¼0·03) breakfast meals. There was a
significant time £ meal interaction for desire to eat something
sweet (P¼0·03) after the participants left the laboratory
(490–730 min). Post hoc comparisons revealed a higher
(P¼0·02) desire to eat something sweet at 610 min for the
PB compared with the WP breakfast meals. There was no
treatment effect on first- and second-meal appetitive responses.
Food intake
Habitual intake and the WP breakfast fat consumption was
higher (P¼0·003) than observed after the control breakfast.
On the other hand, the control breakfast carbohydrate con-
sumption was higher (P¼0·01) than the habitual intake
(Table 4). There was no treatment effect on daily energy
(P¼0·56), protein (P¼0·11) or fibre (P¼0·18) intake com-
pared with the habitual intake. Daily food intake did not
differ (P.0·34) according to the study treatment after the par-
ticipants left the laboratory.
Discussion
The primary aim of the present work was to compare the
effects of peanut consumption (WP or PB) on first- and
second-meal responses. A secondary aim was to contrast
responses to nut form, i.e. whole nut v. butter, on indices
related to obesity and T2DM risk. All test meals (control, PB
and WP) were equally palatable and had a medium glycaemic
index (59·9–66·3).
Compared with the control meal, consumption of a
breakfast meal containing 42·5 g of PB reduced the first-
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290 310 340 370 430 490
–10 15 45 60 90 120 180 240 265
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290 310 340 370 430 490
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290 310 340 370 430 490
Fig. 2. Fasting and postprandial (a) glucose, (b) insulin and (c) NEFA
responses to the breakfast meals containing peanuts ( ), peanut butter
( ) or control ( , no peanuts). Values are means, with their standard errors
represented by vertical bars. * Mean values were significantly different (P,0·05).
Insulin: 1 mU/ml ¼ 6·945 pmol/l.

















response. In addition, the consumption of WP and PB elicited
a significant increase in the postprandial PYY concentration
(180 and 240 min) as well as marked, but non-significant,
GLP-1 and CCK elevations (0–240 min). A reduction on the
second-meal (240–490 min) glycaemic response was also
observed after PB consumption. It also reduced the desire to eat
from 480 to 730min after breakfast. Only preliminary evidence
is available on potential mechanisms accounting for these
outcomes. The observed effects may favour obesity and
T2DM prevention and control, as discussed later.
Glucose metabolism
Although reduced glycaemic responses after peanut(27,28) and
almond(29,30) consumption have been reported by other inves-
tigators, only one trial with almonds has examined the effect
of nut consumption on the second-meal glycaemic response.
It noted improved blood glucose control over successive
meals when almonds or almond oil were added to high-gly-
caemic-index breakfast and lunch meals. In this trial, almond
butter was not effective at moderating blood glucose excur-
sions after the meals(31). No explanation for this finding was
apparent, as the likely mediator, unsaturated fat provided by
the almonds, would have been more bioaccessible from the
almond butter than whole almonds. The present trial exam-
ined the same effect with peanuts, allowing determination of
the reliability and specificity of the responses. The results of
the present study indicate that, in women at elevated risk
for T2DM, the consumption of PB leads to a reduced glycae-
mic response acutely after breakfast and also 240–480 min
later. In contrast to the findings with almonds, the whole nut
responses were slightly weaker. Whether the difference
between peanuts and almonds stems from greater bioaccessi-
bility of lipids and lipophylic compounds from peanuts war-
rants further study. Greater fat availability may reduce the
gastric emptying rate, decrease carbohydrate absorption rate
and favour a reduction of glycaemic response(8). Thus, differ-
ences in the physical form of consumed peanuts can affect
the postprandial glycaemic response. If this hypothesised
mechanism holds, the finding with almond butter remains to
be clarified.
It has been documented that the addition of fat and protein
to meals leads to a reduction of glycaemic response. These
effects have been attributed to delayed gastric emptying
rate(32) and to increased insulin secretion mediated by intesti-
nal hormones (glucose-dependent insulinotropic polypeptide
and GLP-1)(33). Although, in the present study, the fat and pro-
tein content of peanut and the PB breakfasts were very similar
pre-ingestively, the incrementally greater reduction on the
second-meal (240–490 min) glycaemic response observed
after PB consumption suggests that the effect that these
macronutrients exert on glycaemic response may also
depend on food form.
According to the second-meal phenomenon, a reduction of
the first-meal NEFA decreases the second-meal postprandial
glycaemic response(34). This effect is probably due to improve-
ment in insulin sensitivity, as an increase in fatty acid concen-
tration impairs insulin signalling downstream to the insulin
receptor, leading to insulin resistance(35). Therefore, the
lower NEFA concentrations obtained after the consumption
of the PB breakfast may be responsible for the lower glycae-
mic and insulinemic responses 240–480 min later. The extent
of rise in postprandial glycaemia is considered a risk factor
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Fig. 3. Fasting and postprandial (a) glucagon-like peptide-1 (GLP-1), (b) pep-
tide YY (PYY) and (c) cholecystokinin (CCK) responses to the breakfast
meals containing peanuts ( ), peanut butter ( ) or control ( , no pea-
nuts). Values are means, with their standard errors represented by vertical
bars. * Mean values were significantly different (P,0·05).

















consumption might exert a protective effect against this
disorder.
Peanuts contain high concentrations of arginine and pro-
tein, which are insulin secretagogues(5). They also have a
high Zn content that could stimulate the tyrosine kinase recep-
tor, improving insulin sensitivity(37). The high content of MUFA
in PB might also increase insulin sensitivity and favour a
reduction in the glycaemic response in insulin-resistant partici-
pants through increased GLP-1 secretion(38). This also may
explain the second-meal glycaemic IAUC reduction observed
in the present study.
Appetite control and food intake
In the present trial, there was a higher mean GLP-1 IAUC in
the PB and the WP sessions compared with the control ses-
sion. This is consistent with the elevated insulin concen-
trations for these treatments. Similar results were noted in
another study where there was a significant increase in the
GLP-1 concentration 240 min after the consumption of
Korean pine nut oil (Pinus koraiensis) compared with the
control(39). A trend in this direction has also been reported
for almonds (whole and butter)(31).
The high energy density, fibre and protein content of pea-
nuts may augment their satiety property and promote body
weight management(40). A reduction in hunger and in food
intake has been reported in response to nut consumption
(peanuts, PB, almonds and chestnuts) compared with foods
with low energy density (e.g. rice cake and pickles) and a
no-preload condition in healthy participants(41). In a recent
study, higher fullness ratings were observed after almond
meal (whole and butter) than control breakfast meals in glu-
cose-intolerant participants(31). In the present study, there
was a lower desire to eat in response to peanut meals
(whole and butter) compared with the lower-energy density
meal (control meal).
Conclusion
These results indicate that PB can be added to breakfast meals
to favour a reduction on the second-meal glycaemic and the
first-meal NEFA responses, an increase on the first-meal PYY
concentrations and a reduction on the desire to eat in obese
women with high T2DM risk. Effects of WP were in a similar
direction to the PB meal, but not as great. The present findings
have practical implications, because peanuts and PB are often
served in breakfast meals worldwide. Long-term feeding trials
are now required to assess the feasibility and benefits associ-
ated with chronic peanut or tree nut consumption.
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